Chime Biologics Launches Chime AI Platform to Bring Biologics into the Era of AI

November 2, 2025, Vienna, Austria – Chime Biologics, a leading global CDMO that enables its partners' success in biologics, officially launched its Chime AI Platform at the Europe-China Biotech Business Forum during BIO Europe 2025.

The newly launched Chime AI Platform marks a major milestone in integrating artificial intelligence to accelerate biologics from discovery to manufacturing. The platform empowers partners to move from molecule design to commercialization with unprecedented speed, precision, and efficiency by leveraging Chime Biologics' proven global development and manufacturing expertise. It consists of four key components:

  • AI-Powered Biologics Discovery: Using OPUSBio's advanced AI for target selection, antibody design, antibody optimization and developability analysis.
  • AI-assisted Candidate Validation: Accelerating candidate validation through Chime’s dual innovation hubs in Basel and Shanghai.
  • AI-Enhanced Cell Line Development: Achieving high-yield, site-specific integration stable cell lines with shorter development timelines.
  • AI-integrated Fast-track CMC: Leveraging Chime's worldwide GMP facility network for seamless IND/BLA success and commercial readiness.

During the Forum, Chime Biologics and OPUSBio held a signing ceremony to mark their strategic collaboration in AI-powered biologics discovery. The agreement was signed by Jimmy Wei, President of Chime Biologics, and Jianpeng Ma, Founder of OPUSBio.

"The launch of Chime AI marks a defining milestone for Chime Biologics," said Jimmy Wei, President of Chime Biologics. "By integrating AI intelligence into every stage — from discovery to manufacturing — we are empowering global partners to bring next-generation biologics to patients faster than ever before."

"AI has the transformative potential to redefine how biologics are conceived and developed," said Michael Levitt, Nobel Laureate in Chemistry, Co-founder of OPUSBio "The Chime AI Platform demonstrates how the convergence of computation and biotechnology can unlock a new era of intelligent biologics innovation."

Sir Alan Fersht, Co-founder of OPUSBio and a founding pioneer in protein engineering, commented: "AI is now accelerating decades of progress in protein engineering. It enables us to design novel proteins and computationally validate their structures at a scale previously unimaginable. The synergy between AI-powered biologics discovery and Chime Biologics’ advanced CMC capabilities creates a powerful foundation for accelerating biologics innovation."

"Through our partnership with Chime Biologics, we are translating advanced AI algorithms into practical tools that accelerate biologics discovery and development," added Jianpeng Ma, Founder of OPUSBio. "This collaboration combines OPUSBio's leading AI-driven design capabilities with Chime’s proven biologics expertise."

About Chime Biologics

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologic medicines to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 500 skilled employees, we share a common goal to make cutting-edge biomedicines affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally. For more information, please visit www.chimebiologics.com.

About OPUSBio

OPUSBio, a startup company established by the world-renowned scientific team of Drs. Jianpeng Ma (Fudan University, world renowned computational biologist), Michael Levitt (Stanford University, 2013 Nobel Laureate in Chemistry), and Alan Fersht (University of Cambridge, pioneer of protein engineering). The company stands at the forefront of biopharmaceutical innovation and offers a fully integrated, AI-powered platform to accelerate the design, development, and production of next-generation protein drugs. For antibody therapeutics, our capabilities are driven by a proprietary trinity of world-class technologies: a structure-based optimization engine for enhancing existing antibodies with atomic-level precision; a sequence-based intelligence platform for rapid discovery and screening that also optimizes an antibody's overall fitness without requiring structural information; and a groundbreaking ab initio design system to create entirely novel antibodies for previously "undruggable" targets. We embed this powerful technology within a seamless, end-to-end service model that combines the predictive intelligence of an AI-Contract Research Organization (AI-CRO) with a low-risk, high-efficiency manufacturing pathway secured through strategic partnerships with leading CDMOs in China. This unified approach eliminates the fragmentation and costly delays of the traditional drug development lifecycle, providing our partners with a single, streamlined solution to bring superior therapeutics from concept to clinic with unprecedented speed, reduced cost, and a higher probability of success.